Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Firas AK, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Basu S, Ramasamy K. Djebbari F, et al. Among authors: ngu l. Hematology. 2022 Dec;27(1):691-699. doi: 10.1080/16078454.2022.2082725. Hematology. 2022. PMID: 35666686 Free article.
Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N, Poynton E, Alchawaf A, Kassam S, Horan M, Rafferty M, Kelsey P, Scott G, Culligan DJ, Buckley H, Lim YJ, Ngu L, McCulloch R, Rowntree C, Wright J, McKay P, Fourali S, Eyre TA, Smith J, Osborne W, Yallop D, Linton K, Fox CP, Cwynarski K. Martinez-Calle N, et al. Among authors: ngu l. Br J Haematol. 2020 Aug;190(3):394-404. doi: 10.1111/bjh.16592. Epub 2020 Mar 31. Br J Haematol. 2020. PMID: 32232989 Free article.
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Bygrave C, Basu S, Ramasamy K. Djebbari F, et al. Among authors: ngu l. Hemasphere. 2022 May 26;6(6):e738. doi: 10.1097/HS9.0000000000000738. eCollection 2022 Jun. Hemasphere. 2022. PMID: 35651713 Free PMC article.
Frailty subgroup analysis of isatuximab with pomalidomide and dexamethasone in a UK-wide real-world cohort of relapsed myeloma patients.
Djebbari F, Rampotas A, Vallance G, Panitsas F, Basker N, Sangha G, Salhan B, Karim F, Al-Kaisi F, Gudger A, Ngu L, Poynton M, Lam HPJ, Morgan L, Yang L, Young J, Walker M, Tsagkaraki I, Anderson L, Chauhan SR, Maddams R, Soutar R, Triantafillou M, Prideaux S, Obeidalla A, Eyre TA, Bygrave C, Kothari J, Basu S, Ramasamy K. Djebbari F, et al. Among authors: ngu l. Br J Haematol. 2023 Apr;201(1):162-167. doi: 10.1111/bjh.18672. Epub 2023 Jan 31. Br J Haematol. 2023. PMID: 36720464 No abstract available.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Clinical Trial.
A man with a purple leg.
Ngu L, Chooi J, Harmse D, Thomas DW, Davies M. Ngu L, et al. Clin Exp Dermatol. 2009 Jan;34(1):123-4. doi: 10.1111/j.1365-2230.2007.02537.x. Clin Exp Dermatol. 2009. PMID: 19076820 No abstract available.
Venetoclax-based low intensity therapy in molecular failure of NPM1-mutated AML.
Jimenez-Chillon C, Othman J, Taussig D, Jimenez-Vicente C, Martinez-Roca A, Tiong IS, Jain M, Aries J, Cakmak S, Knapper S, Kristensen DT, Murthy V, Galani JZ, Kallmeyer C, Ngu L, Veale D, Bolam S, Orfali N, Parker A, Manson C, Parker J, Erblich T, Richardson D, Mokretar K, Potter N, Overgaard UM, Roug AS, Wei AH, Esteve J, Jädersten M, Russell N, Dillon R. Jimenez-Chillon C, et al. Among authors: ngu l. Blood Adv. 2024 Jan 23;8(2):343-352. doi: 10.1182/bloodadvances.2023011106. Blood Adv. 2024. PMID: 38039513 Free PMC article.
104 results